NeuroPace, Inc. (NASDAQ:NPCE) Q4 2024 Earnings Call Transcript
On March 4, 2025, NeuroPace, Inc., a leading medical device company specializing in the development of implantable neurostimulation systems for the treatment of epilepsy, held its quarterly earnings call for the period ended December 31, 2024. The call was led by Jeremy Feffer, Investor Relations, Joel Becker, Chief Executive Officer and Board Member, and Rebecca Kuhn, Chief Financial Officer, Vice President, Finance and Administration. The following are the key highlights from the call:
Company Participants
- Jeremy Feffer – Investor Relations
- Joel Becker – Chief Executive Officer and Board Member
- Rebecca Kuhn – Chief Financial Officer, Vice President, Finance and Administration
Conference Call Participants
- Priya Sachdeva – UBS
- Rohin Patel – JP Morgan
- Frank Takkinen – Lake Street Capital Markets
- Mike Kratky – Leerink Partners
- Vik Chopra – Wells Fargo
- Matthew Park – Cantor Fitzgerald
- Michael Pollard – Wolfe Research
Financial Performance
During the call, the company reported Q4 revenue of $85.6 million, a 13% increase YoY. Net loss for the quarter was $10.4 million, compared to a net loss of $9.8 million in the same period last year. The company attributed the revenue growth to increased sales of its RNS Neurostimulation System, which is used to treat epilepsy.
Clinical Trials
NeuroPace also provided updates on its ongoing clinical trials. The company announced that it had completed enrollment in its pivotal trial for the treatment of refractory status epilepticus (RSE), a life-threatening condition in which a person experiences continuous seizures. The trial, known as the RES-DEF study, is expected to read out in H2 2026 and will provide data on the safety and efficacy of the RNS System in treating RSE. Additionally, the company announced that it had initiated a study evaluating the use of the RNS System in the treatment of cluster headaches.
Regulatory Approvals
NeuroPace also discussed its regulatory strategy. The company is currently working with the FDA to secure approval for the RNS System for the treatment of RSE. The company expects to submit a pre-market approval application (PMA) in H1 2026. Additionally, NeuroPace is working with regulatory agencies in Europe and Japan to secure approval for the RNS System in those markets.
Impact on Individuals
For individuals with epilepsy, the potential approval of the RNS System for the treatment of RSE could be a game-changer. RSE is a life-threatening condition that can cause significant morbidity and mortality. Currently, there are limited treatment options for this condition, and many patients are left without effective treatment. If approved, the RNS System could provide a new, effective treatment option for these patients.
Impact on the World
The potential approval of the RNS System for the treatment of RSE could have a significant impact on the world. Epilepsy affects over 50 million people worldwide, and approximately 1 in 10 of those individuals have refractory epilepsy. RSE affects a subset of these individuals, and the current treatment options are limited. If approved, the RNS System could provide a new, effective treatment option for these patients, improving their quality of life and potentially saving lives.
Conclusion
NeuroPace’s Q4 2024 earnings call provided important updates on the company’s financial performance and clinical trials. The potential approval of the RNS System for the treatment of refractory status epilepticus could have a significant impact on individuals with this condition and could improve the lives of millions of people worldwide. NeuroPace is working to secure regulatory approvals for the RNS System in various markets, and investors will be closely watching for updates on these approvals.
Investors should continue to monitor NeuroPace’s progress, as the company’s innovative neurostimulation systems have the potential to revolutionize the treatment of epilepsy and other neurological conditions.
